Frequency and correlates of co-morbid psychiatric illness in patients with heroin use disorder admitted to Stikland Opioid Detoxification Unit, South Africa by Dannatt, Lisa Gwen & Weich, Lize
August 2014  Vol. 20  No. 3    -  SAJP    77
ARTICLE
Frequency and correlates of comorbid psychiatric illness in 
patients with heroin use disorder admitted to Stikland Opioid 
Detoxification Unit, South Africa
L Dannatt,1 MB ChB; K J Cloete,1 PhD; M Kidd,2 PhD; L Weich,1 MB ChB, MRCPsych, FCPsych
1 Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa
2 Centre for Statistical Consultation, Stellenbosch University, Cape Town, South Africa
Corresponding author:  L Weich (lizew@sun.ac.za)
Background. There is a lack of studies addressing the frequency and correlates of comorbidities among heroin users admitted for treatment 
in South Africa (SA).
Objective. To assess the frequency and correlates of psychiatric comorbidity among patients with heroin use disorder admitted to the 
Opioid Detoxification Unit at Stikland Hospital in the Western Cape, SA.  
Method. Participants (N=141) were assessed for psychiatric illness (Mini International Neuropsychiatric Interview), comorbid substance 
use disorders (World Health Organization’s Alcohol Smoking Substance Involvement Screening Tool), and legal and social problems 
(Maudsley Addiction Profile). Demographic, personal, psychiatric and substance-use history, in addition to mental state examination on 
admission, were collected from the case notes.  
Results. The largest group of patients (n=56, 40%) had not been abstinent from heroin use since drug debut, and most had been arrested 
for drug-related activities (n=117, 83%) and had family conflicts related to use (n=135, 96%). Nicotine was the most common comorbid 
substance of dependence (n=137, 97%) and methamphetamine was the most common comorbid substance abused (n=73, 52%). The most 
common comorbid psychiatric illness was previous substance-induced psychosis (n=42, 30%) and current major depressive disorder (n=37, 
26%). Current major depressive disorder was significantly associated with females (p=0.03), intravenous drug use (p=0.03), alcohol use 
(p=0.02), and a higher number of previous rehabilitation attempts (p=0.008).  
Conclusion. Patients with heroin use disorders present with high rates of psychiatric comorbidities, which underscores the need for 
substance treatment services with the capacity to diagnose and manage these comorbidities.
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Over the past decade, the number of people using 
illicit substances has increased to around 230 million 
worldwide, with an estimated prevalence of opioid use 
of between 0.6% and 0.8% in the adult population. [1] 
In South Africa (SA), heroin is the most common 
illicit opioid used, with trend statistics across all geographical 
areas showing an increase in the number of patients with heroin 
use disorders presenting for treatment.[2] At the provincial level, 
trend statistics also show an increase in heroin addicts presenting for 
substance treatment, from 1% in Cape Town in 1997 to 17% in the 
Western Cape Province by 2011.
Heroin use leads to euphoria and relaxation[3] as well as alleviation 
of stress, pain and aggression.[4] Ongoing use further leads to 
pervasive and longstanding medical and physical complications, as 
well as social and legal complications.[3] Medical complications of 
heroin use are heterogeneous and may be related to route of use. 
These include: bacterial infections such as infective endocarditis 
and tetanus; viral infections such as HIV and hepatitis B and C;[5] 
talcum pneumonitis due to adulterants; renal complications;[6] and 
accidental overdose and its associated complications.[7] Social and 
legal complications of heroin use are also diverse and may include 
unemployment and interpersonal breakdowns, criminal activity and 
associated legal difficulties,[3] poor living standards and exposure to 
violence.[5]
In addition to the complications discussed above, heroin addicts 
have a high rate of psychiatric comorbidity.[7] An Australian study 
showed that heroin users had a high prevalence of major depressive 
disorder (28%), post-traumatic stress disorder (42%), and personality 
disorders, namely anti-social personality disorder (72%) and 
borderline personality disorder (47%).[7] Similarly, data from the 
Australian Treatment Outcome Study showed that those admitted to 
residential rehabilitation programmes had poor mental health, with 
depression (47%) and social phobia (38%) being particularly prevalent 
in their female sample.[8] A study in Barcelona, Spain, showed that 
heroin users had a high prevalence of personality disorders (40%) 
and found that mood disorders (25.5%) were the most common 
psychiatric comorbidity, followed by anxiety, psychotic disorders 
and eating disorders.[9] In addition to these comorbidities, heroin 
users met criteria for substance abuse or dependence on other 
drugs;[8] Rodriguez-Llera et al.[9] found comorbid use of cocaine 
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(1.3%), alcohol (65.8%), benzodiazepines (55%), cannabis (46.9%), 
other stimulants (49.7%) and hallucinogens (39.6%).
The high rates of psychiatric comorbidity in heroin addicts 
are a major cause for concern.[7] Comorbid psychiatric disorders 
such as personality disorders – specifically borderline personality 
disorder – increase the risk for major depression,[9] which increases 
the risk for high-risk behaviour including overdose and needle 
sharing.[7] Comorbid psychiatric illness or substance abuse is further 
compounded by polysubstance dependence.[9] Of far greater concern 
is that psychiatric comorbidities lead to difficulties in treatment and 
high relapse rates.[7,8] 
In SA, opioid substitution treatment is not considered the mainstay 
of treatment in the public sector; at the time of submission there 
were no state-funded opioid substitution programmes, and only a 
minority of patients are able to self-fund maintenance treatment. The 
Department of Social Development coordinates and funds psycho-
social treatment for heroin addicts while detoxification is provided 
for by the Department of Health. The Opioid Detoxification Unit 
at Stikland Hospital in Cape Town, SA, is a 10-bed ward, and is the 
only dedicated unit for this purpose in the Western Cape. Patients are 
assessed by a medical practitioner on admission and are prescribed an 
individualised reducing regimen of buprenorphine/naloxone or metha-
done. Patients attend a ward programme that includes motivational 
interviewing groups, educational groups and leisure activities. The 
programme’s duration is flexible, with the majority of patients admitted 
for 1 week. After detoxification, patients are expected to attend pre-
arranged in- and outpatient rehabilitation programmes, which employ 
a wide variety of psychosocial treatment methods. 
Studies on the frequency and correlates of comorbidities in heroin 
addicts are imperative in planning effective treatment services for 
patients with heroin use disorders, with specific focus on capacitating 
staff to detect and manage comorbidity among this population. 
However, SA studies addressing the frequency and correlates of 
comorbidities among heroin users admitted for treatment are lacking. 
Local data for those with heroin use disorders may also differ from that 
of international reports based on the changing trends of use, mode of 
administration, comorbid drug use, rate of illegal drug activity, and 
unique sociodemographic patient profile and treatment options.  
Objective
The objective of this study was to assess the frequency and correlates 
of psychiatric comorbidity among patients with heroin use disorder 
admitted to the Opioid Detoxification Unit at Stikland Hospital. Specific 
objectives included: (i) assessing the frequency and nature of previous 
and current comorbid substance use disorders and comorbid psychiatric 
illness, including mood, anxiety, psychosis, eating disorders and 
antisocial personality disorder; and (ii) assessing the correlates of current 
psychiatric comorbidities in terms of demographic data (age, gender and 
level of education) and substance use history (amount of heroin used per 
day, intravenous drug use, number of previous rehabilitation attempts, 
longest period abstinent from heroin and use of other drugs).
Methods
Study design and setting
This was a prospective, descriptive study conducted from 1 April 2012 to 
30 September 2012 at the Opioid Detoxification Unit at Stikland Hospital. 
Participants
During the study period, 220 patients (170 male and 50 female) were 
admitted to the unit. All patients admitted for heroin detoxification 
and willing to participate in the study were included (N=141).
Data collection
Patients were interviewed by the investigator prior to discharge 
when the withdrawal symptoms had resolved, using three 
different screening tools. In addition, demographic and personal 
information,  and information on psychiatric history and substance 
use history was collected from the case notes. The investigator 
who conducted the interviews was trained in administering  the 
screening tools and was blinded to the patients’ mental state on 
admission. 
Screening tools
The Mini International Neuropsychiatric Interview (MINI) was used 
to detect previous and current psychiatric illnesses, including mood, 
anxiety, and psychotic, eating and anti-social personality disorders. 
The MINI is a diagnostic, structured interview developed to detect 
17 disorders described by the Diagnostic and Statistical Manual 
for Mental Disorders, 4th edition (text revision).[10] Sensitivity and 
specificity have been found to be good with most disorders, except 
generalised anxiety disorder, agoraphobia and bulimia.[11] 
The World Health Organization’s Alcohol Smoking Substance 
Involvement Screening Tool was used to detect comorbid substance 
use disorders.[12] This is a simple, easy-to-administer tool used to 
assess use, abuse and dependence across a wide range of substances. 
It is a valid screening tool with suitable sensitivities (54 - 97%) and 
specificities (50 - 96%) across most substances.[12]
The specific subscales of the Maudsley Addiction Profile (sections 
C and E) were used to measure health risk behaviours, health 
problems, and personal and social functioning. The Maudsley 
Addiction Profile was formulated in the UK to assess treatment 
outcome for individuals with drug and/or alcohol problems. It 
is a valid tool with good test-retest reliability.[13] As only subsets 
were used to highlight negative social and legal repercussions by 
answering ‘yes’ and ‘no’ to specific questions, no scoring was done.
Data analysis
Standard data analysis was performed using the Statistica 10 
software package (StatSoft Incorporation, USA). Descriptive 
statistics were used to describe demographic data, frequency and 
type of comorbidities. Associations between psychiatric comorbidity 
and demographic data (age, gender and level of education) as well as 
substance use history (amount of heroin used per day, intravenous 
drug use, number of previous rehabilitation attempts, longest 
period abstinent from heroin and use of other drugs) were assessed 
using the Mann Whitney U-test and χ2 test.  The level of statistical 
significance was set at p<0.05.
Ethical considerations
The Health Research Ethics Committee of Stellenbosch University 
and the Ethics Committee of Stikland Hospital approved the study. 
All participants signed informed consent, while patient anonymity 
was assured by assigning a number to each patient. 
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Results
Participants
Of the 220 patients admitted, 141 were included in the final sample. 
A total of 66 patients (13 females, 53 males) refused to participate, 
while 8 patients (5 females and 3 males) were excluded for the 
following reasons: (i) 4 were admitted for stabilisation of their opioid 
substitution treatment and not detoxification; (ii) 3 were dependent 
on opioids other than heroin; and (iii) 1 was excluded following 
aggressive behaviour towards the investigator. Over the 6-month 
study period, 5 patients were readmitted but were included only once 
in the study. 
Demographic data
The mean (SD) age of participants was 26.5 (5.4) years (Table 1). Most 
participants were male (n=112, 79%), single (n=80, 57%)  and were 
unemployed (n=123, 87%). A Grade 10 level of education had been 
achieved by the highest proportion (n=42, 30%). Four (14%) of the 
female patients were pregnant, while many participants had children 
as dependents (n=65, 46%). Most participants also reported being 
HIV-negative (n=130, 92%).
Substance use history and comorbid substance disorders
The mean (SD) age of drug debut was 14.7 (2.4) years (range 7 - 
26) (Table 2). Most patients (n=97, 69%) used cannabis as drug 
of debut. The mean (SD) age of heroin debut was 19.6 (4.5) years 
(range 14 - 50). Most patients chose to smoke (‘chase’) heroin 
(n=128, 91%) and many (n=60, 43%) used one to five units of 
heroin per day, bought as bags or quarters of a gram (‘beats’). 
The majority of participants supported their heroin use by theft 
(n=109, 77%). Those admitted for detoxification and rehabilitation 
for the first time amounted to 50 (36%). A high proportion of 
participants (n=56, 40%) had never been abstinent since their 
heroin debut and the majority (n=78, 55%) had five or fewer prior 
rehabilitation attempts. 
The most frequent (n=73, 52%) substance of abuse was crystal 
methamphetamine (colloquially referred to as tik), while the most 
frequent (n=137, 97%) substance of dependence other than heroin 
was nicotine (Table 3).
Previous and current psychiatric comorbidities
There were unexpectedly high rates of previous substance-induced 
psychosis (n=42, 30%) (Table 4). This was the most prevalent 
previous comorbid disorder and was found in patients abusing 
methamphetamine (n=26, 36%), cannabis (n=13, 45%) and 
methaqualone (n=38, 27%) (methaqualone is usually used with 
cannabis as ‘white pipe’). Many patients used more than one drug 
and in patients with a past history of using multiple illicit drugs 
simultaneously, it was difficult to identify the causative agent. 
The most common current comorbidity was major depressive 
disorder, with more than one in four patients meeting criteria for 
this disorder (n=37, 26%). Rates of anxiety disorders were also high 
(n=28, 20%), with post-traumatic stress disorder being the most 
frequent previous (n=13, 9%) and current (n=11, 8%) comorbidity 
in the group. 
Anti-social personality disorder was found in 83 (59%) of patients. 
This is the only axis II disorder screened for by the MINI.
Legal and social repercussions
Most participants (n=117, 83%) had been arrested for drug-related 
activities, with fewer who had been sentenced (n=44, 31%) or had 
pending court dates (n=23, 16%) (Table 5). 
The most common social problem was addiction-related family 
conflict (n=135, 96%). Only one patient denied social difficulties and 
it is notable that he had only been using for a few months.
Correlates of current psychiatric comorbidity
Major depressive disorder was significantly associated with females 
(p=0.03), intravenous drug use (p=0.03), alcohol use (p=0.02), and 
a high number of previous rehabilitation attempts (p=0.008). Post-
Table 1. Demographic data of the sample (N=141)
Age, years (mean (SD)) 26.5 (5.4)
Sex, n (%)
Male 112 (79)
Female 29 (21)
Marital status, n (%) 
Single 80 (57)
Married 13 (9)
Divorced 5 (4)
Separated 4 (3)
In a relationship with a partner 39 (28)
Highest level of education, n (%)
Grade 3 1 (1)
Grade 6 1 (1)
Grade 7 6 (4)
Grade 8 12 (9)
Grade 9 28 (20)
Grade 10 42 (30)
Grade 11 11 (8)
Grade 12 30 (21)
Tertiary 10 (7)
Employment, n (%)
Employed 18 (13)
Unemployed 123 (87)
Dependents, n (%)
Children 65 (46)
Partner 27 (19)
Parents 1 (1)
Pregnant, n (%)
Yes 4 (14)
No 25 (86)
HIV-positive, n (%)
Yes 4 (3)
No 130 (92)
Not tested 7 (5)
SD = standard deviation.
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traumatic stress disorder was significantly associated with female 
gender (p=0.0009), while panic disorders plus agoraphobia were 
significantly associated with a lower level of education (p=0.03).
Discussion
This study is the first to focus on frequency and correlates of psychiatric 
comorbidity in patients with heroin use disorder presenting for treatment 
at the Opioid Detoxification Unit at Stikland Hospital. Of the 141 
Table 2. Substance use history of participants (N=141)
Age of drug debut, years (mean, (SD)) 14.7 (2.4)
First drug used, n (%)
Nicotine 27 (19)
Cannabis 97 (69)
Alcohol 13 (9)
Psychedelics 3 (2)
Sedatives 0 (0)
Volatile substances 0 (0)
Cocaine 6 (4)
Methamphetamine 31 (22)
Heroin 9 (6)
Methaqualone 16 (11)
Age of heroin debut, years (mean, (SD)) 19.6 (4.5)
Units of heroin used, n (%)
1 - 5   60 (43)
6 - 10 58 (41)
11 - 15 19 (13)
16 - 20 4 (2)
26 - 30 2 (1)
Route of heroin administration, n (%)
Smoked/chased 128 (91)
Injected 17 (12)
Snorted 4 (3)
Previous rehab attempts, n (%)
None 50 (36)
1 - 5 78 (55)
6 - 10 5 (4)
11 - 15 2 (1)
26 - 30 1 (0.7)
31 - 35 1 (0.7)
Longest time clean since dependent, months (n, (%))
Never 56 (40)
1 - 5 34 (24)
6 - 10 24 (17)
11 - 15 4 (3)
16 - 20 9 (6)
21 - 25 7 (5)
36 - 40 4 (3)
46 - 50 1 (0.7)
51 - 55 1 (0.7)
55 - 60 1 (0.7)
Theft 109 (77)
Family 38 (27)
Drug dealing 35 (25)
Hustling/conning (‘skarreling’) 18 (13)       
Continued...
Table 2 (continued). Substance use history of participants 
(N=141) 
Means of funding drug habit, n (%)
Employment 17 (12)
Violent crime 17 (12)
Fraud 10 (7)
Prostitution 6 (4)
 Providing a safe place (‘suikerhuisie’) for others to use in 
exchange for drugs
4 (3)
SD = standard deviation.
Table 3. Frequency of current comorbid substance use disorders 
in the sample (N=141)
Substance Substance abuse, 
n (%)
Substance dependence, 
n (%)
Heroin 0 (0) 141 (100)
Nicotine 3 (2) 137 (97)
Cannabis 30 (21) 13 (9)
Alcohol 34 (24) 2 (1)
Methaqualone 30 (21) 2 (1)
Cocaine 6 (4) 4 (3)
Methamphetamine 73 (52) 13 (9)
Psychedelics 2 (1) 0 (0)
Sedatives 4 (3) 9 (6)
Volatile substances 0 (0) 0 (0)
Table 4. Frequency of previous and current psychiatric comor-
bidities in the sample (N=141)
Comorbidity Past, n (%) Current, n (%)
Major depressive disorder 30 (21) 37 (26)
Bipolar disorder 1 1 (1) 1 (1)
Bipolar disorder 2 0 (0) 1 (1)
Panic disorder with agoraphobia 0 (0) 6 (4)
Panic disorder without agoraphobia 0 (0) 1 (1)
Generalised anxiety disorder 0 (0) 1 (1)
Social phobia 1 (1) 8 (6)
Post-traumatic stress disorder 13 (9) 11 (8)
Obsessive compulsive disorder 0 (0) 1 (1)
Substance-induced psychosis 42 (30) 0 (0)
Bulimia 1 (1) 0 (0)
Anorexia 1 (1) 0 (0)
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patients who participated in his study, the majority were male, single 
and were unemployed. The highest proportion of participants had 
a Grade 10 level of education. Of the female participants, 14% were 
pregnant, while most patients were HIV-negative (based on self-reports). 
Furthermore, most participants smoked rather than injected heroin, in 
contrast to reports by other studies.[7,9] This finding for mode of heroin 
administration holds true for the current pattern of heroin use in SA.[14]
The average age of patients with heroin use disorders presenting 
for treatment at this facility correlated with findings from the SA 
Community Epidemiology Network on Drug Use project, a surveillance 
project that monitors substance use trends in substance treatment 
programmes, reporting a mean age of 23 - 27 years for patients using 
heroin in the Western Cape.[2] However, the age of heroin debut was 
younger, at 19 years, with only nine participants using heroin as their 
debut drug; most used cannabis followed by methamphetamine as drug 
of debut. Similarly, the Australian Treatment Outcome Study reported 
an average age of 19 years for first heroin use.[7] Drug debut in the 
adolescent years could possibly be explained by the imbalance between 
developing prefrontal regions and more-matured limbic regions, which 
increases vulnerability to reward mechanisms such as substances.[15]  
With regard to comorbid substance use, nearly all participants were 
dependent on nicotine, which has not been reported in other studies. 
Other studies have shown a high rate of alcohol, sedative, cocaine and 
psychedelic abuse.[8,9] The most common substance of abuse was crystal 
methamphetamine (‘tik’), which is not surprising, as methamphetamine 
is the most common primary drug of abuse among patients in substance 
treatment programmes in the Western Cape.[14] Other substances 
most commonly abused included alcohol, followed by cannabis and 
methaqualone (a tablet that is sold on the street, which is crushed and 
mixed with cannabis, and smoked in the broken-off neck of a bottle; 
called ‘mandrax’, ‘buttons’ or ‘white pipe’). This is consistent with the 
findings of the SA Stress and Health study, a household survey which 
showed that alcohol was the most commonly used addictive substance 
in SA, followed by nicotine and cannabis.[16] Participants may have 
been using these depressive substances to manage heroin withdrawal 
symptoms as they are relatively inexpensive and readily available. 
Previous and current psychiatric comorbidities were particularly 
frequent in this sample, which is also reflected in other reports.[7,9]  The 
most common current comorbidity in this study was major depressive 
disorder, followed by post-traumatic stress disorder, social phobia and 
panic disorder, while previous psychiatric comorbidities included a 
similar spectrum comprising major depressive disorder, post-traumatic 
stress disorder and panic disorder. An unexpected finding was that many 
patients reported previous psychotic episodes. Heroin use disorder is 
rarely associated with psychosis, as confirmed by other studies,[8,9] and 
most patients linked methamphetamine and cannabis use with psychosis. 
Cannabis is well described to cause transient psychotic symptoms or 
exacerbate underlying psychoses,[17] while methamphetamine is strongly 
associated with transient psychosis. [18] However, none of the patients in 
this study were treated for psychosis or were psychotic during evaluation. 
The aforementioned psychiatric comorbidities could be a complication 
related to pre-existing psychiatric illnesses that led to heroin use in 
order to self-medicate symptoms, or due to an underlying social factor 
that the participant was struggling to escape (even metaphorically), for 
example homelessness, isolation, abuse or prostitution. 
In terms of the correlates of psychiatric comorbidity, female gender 
was a significant correlate for major depressive disorder and post-
traumatic stress disorder. Previous international studies report contra-
dicting data, with some studies showing a female predominance for 
major depressive disorder and post-traumatic stress disorder,[7,8] while 
others show no gender differences.[9] Alcohol use was also a significant 
correlate for major depressive disorder, which may be a cause-or-effect 
association. High rates of alcohol use can induce depression, as shown 
by a study completed in New Zealand.[19] Alternatively, alcohol as a 
sedating agent can be used to self-medicate depression.
With specific emphasis on the social and legal complications 
of heroin use in this sample, most participants had high levels of 
isolation and family conflict. Furthermore, drug-related criminal 
activity and arrests were particularly common as most participants 
funded their substance use disorder with theft, drug dealing and 
hustling (locally referred to as ‘skarreling’). Although diversion 
programmes are suggested as management of substance-dependent 
offenders, this is not yet national policy.[20] However, some patients 
reported being offered rehabilitation instead of a sentence. 
Just over half of the participants had attempted previous rehabili-
tation, while the Australian Treatment Outcome Study reported >90% 
of patients having attended rehabilitation programmes.[7] The low 
rate of participants with previous rehabilitation attempts highlights 
the many barriers to accessing substance treatment services within 
the Western Cape,[21] or possibly a new, emerging epidemic in this 
province.[22] Furthermore, most participants who attended rehabili-
tation programmes were either abstinent for only a short period or 
started using immediately following treatment. This could be either 
ascribed to the efficacy of the current treatment regimens or the 
pervasive and unrelenting nature of heroin addiction.[22]
Study limitations
This prospective study included a relatively small sample size. 
All tools relied on self-reporting of symptoms. Furthermore, the 
Table 5. Frequency of legal and social repercussions in the 
sample (N=141)
Variable n (%)
Legal problems 
Arrests 117 (83) 
Sentences 44 (31) 
Pending 23 (16) 
None 20 (14)
Social problems
Conflict at home 135 (96) 
Loss of contact with family 94 (67) 
Violence 18 (13) 
Partner using 16 (11) 
Needle sharing 11 (8) 
Multiple partners 11 (8) 
Homelessness 8 (6) 
Prostitution 6 (4) 
None 1 (1)
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population of patients admitted to Stikland Hospital may not be truly 
representative of the SA population. 
Conclusion
Patients with heroin use disorders present with high rates of psychiatric 
comorbidities that underscore the need for substance treatment 
services aimed at diagnosing and managing these comorbidities.
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